Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses

Area of Science:

• Biotechnology
• Genetics
• Medical Ethics

Background:

• The first individualized therapy, milasen, was developed two years ago for a rare genetic mutation causing Batten disease.
• There has been a significant increase in developing customized treatments for extremely rare genetic conditions.
• These novel interventions raise ethical concerns typical of new therapeutics.

Purpose of the Study:

• To examine the ethical, legal, and regulatory challenges posed by individualized gene therapies.
• To urge multidisciplinary stakeholder engagement for addressing these complex issues.
• To recommend initial policy responses for navigating this evolving landscape.

Main Methods:

• Analysis of ethical concerns associated with novel therapeutics.
• Examination of legal and regulatory challenges in individualized treatments.
• Review of policy implications for research versus treatment distinctions.

Main Results:

• Individualized therapies blur the line between research and treatment, necessitating policy reevaluation.
• Concerns include compromised informed consent, conflicts of interest, and justice issues related to high costs.
• Existing legal and ethical frameworks are challenged by these customized interventions.

Conclusions:

• Multidisciplinary stakeholder engagement is crucial for transparent and practical solutions.
• Policy responses are needed to address the unique challenges of individualized gene therapies.
• Ethical considerations must guide the development and implementation of these advanced treatments.